Sarvodaya Hospital Becomes First in India to Offer Terbium-161 PSMA Therapy for Advanced Prostate Cancer
Key Insights
Sarvodaya Hospital in Faridabad has become India's first theranostics and nuclear medicine center to introduce Terbium-161 PSMA (search) therapy for metastatic castration-resistant prostate cancer.
The hospital has simultaneously launched CAR-T cell therapy for blood cancers including leukemia, lymphoma, and multiple myeloma, creating comprehensive cancer care under one roof.
This targeted therapy represents a significant advancement in precision oncology, delivering radiation directly to cancer cells while sparing healthy tissue.
Sarvodaya Hospital in Faridabad, Delhi NCR, has achieved a landmark milestone by becoming India's first theranostics and nuclear medicine center to offer Terbium-161 PSMA (search) therapy for patients with advanced prostate cancer. This groundbreaking development brings new hope to patients battling metastatic castration-resistant or hormone-refractory prostate cancer who previously had limited treatment options.
Revolutionary Targeted Therapy Approach
The Terbium-161 PSMA (search) therapy represents a significant breakthrough in precision oncology, utilizing targeted nuclear medicine to deliver radiation directly to cancer cells while sparing healthy tissue. This approach is part of a growing global shift toward personalized nuclear medicine treatments that offer more precise therapeutic interventions.
"This groundbreaking therapy will bring renewed hope to patients battling advanced prostate cancer," said Dr. Swagat Dash, Head of Department and Senior Consultant, Nuclear Medicine at Sarvodaya Cancer Institute. "It marks a major step forward in precision oncology, and our team remains dedicated to delivering the most advanced and effective cancer care available."
Comprehensive Cancer Care Integration
In addition to pioneering the Terbium-161 PSMA (search) therapy, Sarvodaya Hospital has simultaneously launched CAR-T cell therapy, one of the most advanced treatments for blood cancers including leukemia, lymphoma, and multiple myeloma. This dual launch creates a comprehensive cancer care ecosystem that spans from diagnosis to the most sophisticated treatment modalities under one roof.
The integration of both therapies positions Sarvodaya Hospital among the few institutions in India capable of delivering end-to-end cancer care, from initial diagnosis through complex immunotherapy and targeted radiation treatments.
Leadership in Precision Oncology
Dr. Dinesh Pendharkar, Director of Sarvodaya Cancer Institute, emphasized the significance of this development: "We are honoured to pioneer this revolution in India. Terbium-161 PSMA (search) therapy represents a novel approach to treating advanced prostate cancer. We are shifting the landscape in terms of what complete cancer care means—with CAR-T cell therapy as well as theranostics."
The hospital's commitment to evidence-based treatment approaches reflects its focus on next-generation cancer solutions that improve patient outcomes through innovative therapeutic strategies.
Setting New Standards in Oncology
This milestone reinforces Sarvodaya Hospital's leadership in advanced cancer care and establishes new benchmarks in oncology treatment within India. The introduction of these cutting-edge therapies represents a defining moment for precision oncology in the country, offering patients access to world-class cancer care that was previously unavailable domestically.
The hospital's pioneering approach to integrating multiple advanced cancer therapies demonstrates its commitment to reshaping comprehensive oncology services and providing patients with the most effective treatment options available in modern cancer care.